|
Post by afrezzamiracle on Jan 5, 2016 20:00:28 GMT -5
In sharp contrast to the original post of this thread I smell no fear what so ever, and anyone who thinks it's game over for Al Mann has lost their mind! 100% of AFREZZA has been returned to MNKD (with robust patent protection until 2031), 100% of TechnoSphere is ours and the future is beyond bright! The time has never been better to back up the truck (or semi!).
|
|
|
Post by anderson on Jan 5, 2016 21:25:46 GMT -5
Only let's wait until the effective termination date so MannKind keeps all the profit. Umm didnt SNY already loose its exclusive hold on Afrezza when they sent the letter to MNKD. MNKD can sell to whoever they want now and not give SNY anything. The partnership still has inventory to sell out of and that is the only place SNY will make/loose more money on Afrezza. This is good since we dont want patients to go without Afrezza.
|
|
|
Post by mnholdem on Jan 5, 2016 21:33:56 GMT -5
You may be on to something there. Of course, the rumored $200 million order is just that: a rumor, isn't it? Al?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 22:11:06 GMT -5
You may be on to something there. Of course, the rumored $200 million order is just that: a rumor, isn't it? Al? There are diabetics outside of US who would gladly pay out of pocket if cheap enough... Lots of them
|
|
|
Post by dreamboatcruise on Jan 5, 2016 23:20:03 GMT -5
Agree with that, but that is easier said than done. The cash burn is about to increase substantially because the Sanofi credit line will get cut off and the portion of the losses that have been paid by Sanofi are about to become cash charges to Mannkind. Good news, MNKD can now keep 100% of the revenue. Bad news, MNKD can now pay 100% of the expense and working capital expenditures on their own. We know the drug wasn't profitable before all this happened, and Matt pretty clearly said they are going to cut the price to drive adoption. That is going to eat the cash very quickly and don't forget that some of the cash is restricted to payment back to Deerfield.
Raising money for a company with a 75 cent stock is going to be a neat trick. If Matt manages to pull it off, he will deserve a lot of people's thanks.
matt MNKD has other options than "raising money." They could sell a boatload of Afrezza to some friendly country like Israel to quickly get a stash of cash . I'm guessing Israel in general isn't nearly as friendly after the last boatload MNKD sold them.
|
|
|
Post by esstan2001 on Jan 5, 2016 23:22:39 GMT -5
oy vey.
|
|
|
Post by dreamboatcruise on Jan 6, 2016 1:35:56 GMT -5
In all seriousness (actually not really) regarding the topic thread, after a meeting years ago I had a colleague dissect my body language and verbal tone... it was amazing the things he read into my remarks which mainly had to do with what turned out to be over ripe sushi I had for lunch. I reserve judgement on Matt's tone until there is some actual information he conveys... other than the obligatory optimism.
|
|
|
Post by mnkdfann on Jan 6, 2016 1:48:36 GMT -5
Nope. It's just starting. To you SNY - watch how Americans handle this. Well, first the Americans at MNKD turned to France (Sanofi) and then to Israel (TASE). Maybe they try Germany or England next?
|
|
|
Post by mnholdem on Jan 6, 2016 8:11:18 GMT -5
In all seriousness (actually not really) regarding the topic thread, after a meeting years ago I had a colleague dissect my body language and verbal tone... it was amazing the things he read into my remarks which mainly had to do with what turned out to be over ripe sushi I had for lunch. I reserve judgement on Matt's tone until there is some actual information he conveys... other than the obligatory optimism. dbc - Speaking of body language, I have been thinking about publishing a book entitled, "How to Read Body Language in Braille". I've tested it on a few ladies and they thought it could easily become a best-seller.
Seriously, regardless of how Matt "sounded" I would think that all the Officers and Directors are angry. After all, their vested Options-to-Buy awards are now worthless, since most of those were set up in 2013 with a strike price in the $2-$4 range.
|
|
|
Post by curiousdoc on Jan 6, 2016 8:21:23 GMT -5
I can't understand the blind optimism here regarding this split. Yes, sny sucked. But there is a reason mnkd partnered. They do not have the resources nor means to go it alone, 100℅ profits or not.
If you thought the sny deal was bad, they have zero bargaining power with a next potential partner. Especially considering sny kicked us in the ass as they showed us the door with their comments on profitability.
|
|
|
Post by rockstarrick on Jan 6, 2016 8:28:09 GMT -5
I can't understand the blind optimism here regarding this split. Yes, sny sucked. But there is a reason mnkd partnered. They do not have the resources nor means to go it alone, 100℅ profits or not. If you thought the sny deal was bad, they have zero bargaining power with a next potential partner. Especially considering sny kicked us in the ass as they showed us the door with their comments on profitability. What good is a partner that has no intention of you surviving ?? We were doomed with Sanofi, this is our only option, hard to believe, but true.
|
|
|
Post by jbe on Jan 6, 2016 8:38:25 GMT -5
I can't understand the blind optimism here regarding this split. Yes, sny sucked. But there is a reason mnkd partnered. They do not have the resources nor means to go it alone, 100℅ profits or not. If you thought the sny deal was bad, they have zero bargaining power with a next potential partner. Especially considering sny kicked us in the ass as they showed us the door with their comments on profitability. Sanofi made themselves look bad on this deal, a few magazine ads and doubling the price of Afrezza compared to insulin pens? And they complain about lack of sales? I hope MNKD cuts the price in half, and hires some trucking company to deliver to CVS, rite aid, Walmart etc just do east coast if necessary....sell via mail order etc, go cheap, just make it economical to get it out to the diabetics interested. Give Afrezza a chance to compete directly against pens, it will win, if the price is competitive.
|
|
|
Post by curiousdoc on Jan 6, 2016 8:46:32 GMT -5
I never said the partnership was good. In fact all along I felt like we were getting sand bagged. That doesn't change the dire financial situation we are in. It was a catch-22 situation
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 9:12:13 GMT -5
I can't understand the blind optimism here regarding this split. Yes, sny sucked. But there is a reason mnkd partnered. They do not have the resources nor means to go it alone, 100℅ profits or not. If you thought the sny deal was bad, they have zero bargaining power with a next potential partner. Especially considering sny kicked us in the ass as they showed us the door with their comments on profitability. SNY comments (http://www.cnbc.com/2016/01/05/reuters-america-update-1-poor-sales-prompt-sanofi-to-pull-plug-on-mannkind-inhaled-insulin.html) A Sanofi spokesman said Afrezza continued to suffer from a low level of prescriptions, despite substantial sales efforts. "The product never met even modest expectations and we do not project Afrezza reaching even the lowest patient levels anticipated at the time of entering the license and collaboration agreement, while costs are projected to remain very high for a significant period of time," he said. I've been theorizing that SNY couldn't lower the price due to the cost structure. If they lowered the price, what would be the point of selling afrezza? (from a business point of view, not a health point of view). If MNKD survives for a few years and keeps control of afrezza and tries to pick up sales and marketing, then we'll get a much clearer financial picture. Till then, we can only guess. But any company mnkd wants to partner with aren't going to be happy with what they know so far in terms of insurance coverage, pricing, sales, and mnkd's current financial condition all of which, as you point out, gives mnkd zero bargaining power with any new suitor.
|
|
|
Post by rockstarrick on Jan 6, 2016 9:24:12 GMT -5
I never said the partnership was good. In fact all along I felt like we were getting sand bagged. That doesn't change the dire financial situation we are in. It was a catch-22 situation Yes I know, as bad as things are, I would rather this than another year of Sanofi bleeding us out. I hope diabetics boycott Sanofi.
|
|